Pain Patients Can Have Good Outcomes With Long-Term Opioids

Pain Patients Can Have Good Outcomes With Long-Term Opioids
ISSUE: AUGUST 2014 | VOLUME: 12(8)

Long-term opioid treatment can produce positive outcomes in chronic noncancer pain when physicians prescribe it carefully to individuals who have low risks for addiction and overdose, according to the results of a systematic review.

Andrea Furlan, MD, PhD, and her colleagues searched Medline, EMBASE, CINAHI, PsycINFO, Central and Business Source Premier for studies published since 2000 on function and quality of life (QOL) in patients taking long-term opioids for chronic noncancer pain.

The studies included in the analysis involved chronic noncancer pain that lasted longer than three months, opioid use for longer than three months, and outcomes that included measures of function and QOL. Most of the studies excluded patients who had comorbidities and psychiatric diagnoses. The majority of the patients were monitored closely by health care professionals, and were on doses of opioids that were less than approximately 200 mg per day.

To read more please click on this link:



States Have Wide Narcotic Use Rate Differences

States Have Wide Narcotic Use Rate Differences

Louisiana and New York state have the highest amount of narcotics use in workers’ compensation cases among the 25 states included in a recent study. The research, conducted by the Workers Compensation Research Institute (WCRI) in Cambridge, Mass., found nearly a fourfold variation between the high- and low-use states.

“This is part of an ongoing series starting in 2011,” said Dongchun Wang, an economist at WCRI and an author of the latest published study, “Interstate Variations in Use of Narcotics, Second Edition.”

To Read More Please Click On This Link:

When the Pain Won’t Stop

When the Pain Won’t Stop

If your back pain or neck pain has persisted despite a variety of treatments, and maybe even after spine surgery, you may feel frustrated and miserable. Pain can be exhausting and cruel – making it hard for you to function.
Every day we witness the impact pain has on our forum members and social media visitors. To help you better understand how pain works, and treatment approaches, here are a few pointers.

All pain is real

To read more please click on this link:

Anger, Pain & Relationships

Anger, Pain and Relationships

By Linda Ruehlman

Living with chronic pain can be very frustrating. Not surprisingly, people with chronic pain tend to report greater levels of anger than those without pain. Expressions of anger differ, with some people being more likely to suppress and hide it, turning it inward on themselves, and others turning it outward, letting it explode.  Still others struggle to be someplace in-between – hoping for “healthy expression” of anger that allows the angry person to express his/her feelings without being aggressive.

How you express your anger can make a difference – the in-between approach may be best over the long-run. I have written before about anger management. Today I want to talk a bit about the consequences of anger and how to prevent anger from starting in the first place. In general, high levels of anger have been found to increase both acute and chronic pain, reason enough to try to prevent it!  Besides making pain worse, anger can also take a toll on your relationships, especially with family. For example, recently, a reader wrote to me:

“Sometimes when I have a migraine, I lose my temper and treat my husband badly. I realize that this has hurt our relationship. How can I undo the damage and prevent myself from snapping at him in the future?”

Relationship Repair


To Read More Please Click On This Link:


FDA Approves Omidria for Use in Cataract and Other Intraocular Lens Replacement Procedures

FDA Approves Omidria for Use in

Omeros Corporation (NASDAQ: OMER) today announced that the U.S. Food and Drug Administration (FDA) has approved Omidria (phenylephrine and ketorolac injection) 1%/0.3% for use during cataract surgery or intraocular lens replacement (ILR) to maintain pupil size by preventing intraoperative miosis (pupil constriction) and to reduce postoperative pain. The approval comes with no post-marketing commitments other than the previously agreed study of Omidria for use in pediatric patients, which, if successfully completed, makes the drug eligible for an additional six months of marketing exclusivity in the U.S. Omidria, the first commercial product from Omeros’ PharmacoSurgery® platform, is a proprietary combination of a mydriatic (pupil-dilating) agent and an anti-inflammatory agent that is added to irrigation solution standardly used during cataract surgery and other ILR procedures (e.g., refractive lens exchange), collectively the most common surgical procedures performed in the U.S. at nearly four million annually. Omidria is the only FDA-approved product for intraocular use that prevents intraoperative miosis and reduces postoperative pain, providing consistent and predictable management of both of these ILR-related problems for ophthalmic surgeons and their patients. To read more, please click on this link: